Fortrea Holdings (FTRE) Accounts Payables (2022 - 2026)
Fortrea Holdings (FTRE) posted Accounts Payables of $70.8 million for Q1 2026, up 138.38% on a QoQ basis from $29.7 million in Q4 2025, and down 35.75% year-over-year from $110.2 million in Q1 2025.
Fortrea Holdings (FTRE) Accounts Payables (2022 - 2026) Analysis & Trends
Fortrea Holdings' Accounts Payables history runs 5 years deep, the most recent figure standing at $70.8 million for Q1 2026.
- Quarterly Accounts Payables fell 35.75% year-over-year to $70.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $70.8 million (down 35.75% YoY) and the FY2025 annual result came in at $29.7 million, down 78.51% from the prior year.
- Accounts Payables was $70.8 million for Q1 2026 at Fortrea Holdings, up from $29.7 million in the prior quarter.
- Across five years, Accounts Payables topped out at $144.2 million in Q2 2024 and bottomed at $29.7 million in Q4 2025.
- A 5-year average of $104.0 million and a median of $110.2 million in 2025 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2023 — Accounts Payables jumped 63.07% — and 2025, when it plunged 78.51%.
- Fortrea Holdings' Accounts Payables stood at $81.5 million in 2022, then soared by 63.07% to $132.9 million in 2023, then advanced by 3.99% to $138.2 million in 2024, then plunged by 78.51% to $29.7 million in 2025, then jumped by 138.38% to $70.8 million in 2026.
- Business Quant data shows FTRE's Accounts Payables at $70.8 million in Q1 2026, $29.7 million in Q4 2025, and $49.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | 5.74 Mn |
| 2 | Nanobiotix | 1,908.96 Bn | 1,908.90 Bn | - | 10.62 Mn |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | 8.64 Mn |
| 4 | BeOne Medicines | 474.03 Bn | 469.24 Bn | 1.35 Bn | 423.55 Mn |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | 489.30 Mn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | 1.03 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | 1.52 Bn |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Fortrea Holdings | 1.83 Bn | 1.68 Bn | 123.60 Mn | 70.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 70.80 Mn |
| Dec 31, 2025 | 29.70 Mn |
| Sep 30, 2025 | 49.50 Mn |
| Jun 30, 2025 | 92.60 Mn |
| Mar 31, 2025 | 110.20 Mn |
| Dec 31, 2024 | 138.20 Mn |
| Sep 30, 2024 | 137.60 Mn |
| Jun 30, 2024 | 144.20 Mn |
| Mar 31, 2024 | 131.30 Mn |
| Dec 31, 2023 | 132.90 Mn |
| Sep 30, 2023 | 128.30 Mn |
| Jun 30, 2023 | 105.30 Mn |
| Dec 31, 2022 | 81.50 Mn |